American Injectables Announces Strategic Leadership Appointments
Travis Allen, who has been instrumental in American Injectables' development since its founding, has been appointed CEO and Board Director. Paul Campanelli, former CEO of Endo International and Par Pharmaceutical, will transition to the role of Executive Chairman, while Kimberlee Steele, MD of North America at SHL Medical, joins as a new Board Member.
Global Pharma | 15/02/2025 | By Manvi | 183
Nexus Pharmaceuticals Secures FDA Approval for Tacrolimus Injection
Tacrolimus Injection 5 mg/mL (Single-Dose Vial) in a 10-pack will be launching soon.
Global Pharma | 15/02/2025 | By Aishwarya | 492
Alcami Appoints Tori E. Arens as President-Drug Product
In this role, Arens will lead the cGMP drug product manufacturing operations at Alcami.
Global Pharma | 15/02/2025 | By Aishwarya | 338
Aurora Pharmaceutical Announces Availability of EquiCoxib
Aurora Pharmaceutical announced the availability of EquiCoxib, the FDA-approved generic equivalent of Equioxx® (firocoxib), a non-steroidal anti-inflammatory drug (NSAID) used for pain and inflammation associated with osteoarthritis.
Global Pharma | 14/02/2025 | By Manvi | 464
Akeso Announces IND Acceptance for AK139
Akeso, Inc. announces the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2. AK139 is under investigation for a number of indications, including respiratory and skin diseases.
Global Pharma | 14/02/2025 | By Manvi | 766
Tillotts Pharma AG Celebrates 15 Years Anniversary as Part of Japanese Zeria Group
This commitment has also led to Tillotts in-licensing the product Dificlir™ for the treatment of Clostridioides difficile infection (CDI) in 2020, a potentially life-threatening disease.
Global Pharma | 14/02/2025 | By Aishwarya | 458
Clinigen and Essential Pharma to Improve Patient Access in JAPAC
IOPIDINE 5mg/ml is a short-term adjunctive therapy for patients with chronic glaucoma on maximally tolerated medical therapy to prevent or control intraocular pressure.
Global Pharma | 14/02/2025 | By Aishwarya | 644
JuliaHub Doubles Investment in Advanced Pharmaceutical Modeling Platform
JuliaHub simplifies complex pharmaceutical workflows by integrating analytics such as modeling and simulation in pharmacometrics.
Global Pharma | 14/02/2025 | By Aishwarya | 791
Antengene Announces XPOVIO Approved for Public Health Insurance Coverage in Taiwan Market
With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in nine countries and regions in APAC, and included in the public insurance schemes in five of those markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea).
Global Pharma | 13/02/2025 | By Manvi | 792
Burkert Fluid Control Systems Acquires Stake in Green Elephant Biotech
The partnership gives Bürkert access to the latest trends and developments in the biopharmaceutical industry, one of the strategic core markets of the fluidics specialist from Ingelfingen.
Global Pharma | 13/02/2025 | By Aishwarya | 727
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy